This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Qiagen (QGEN) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of -2.94% and -1.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100
by Zacks Equity Research
Inovio (INO) closes enrollment in the phase II study, evaluating VGX-3100 for the treatment of HPV-related vulvar dysplasia.
Inovio Up on Enrollment Closure in Cervical Dysplasia Study
by Zacks Equity Research
Inovio (INO) concludes enrollment in the phase III study (REVEAL 1), which currently evaluates VGX-3100 for the treatment of cervical dysplasia, caused by HPV. Shares rally.
QIAGEN Inks Distribution Deal With Mckesson Medical-Surgical
by Zacks Equity Research
The distribution agreement will enable QIAGEN (QGEN) to expand reach in the healthcare market.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now
by Zacks Equity Research
QIAGEN (QGEN) is enjoying investors' high confidence, courtesy of the QIAstat-Dx system.
QIAGEN-DiaSorin Union to Enhance QuantFERON for Lyme Disease
by Zacks Equity Research
QIAGEN (QGEN) expects multi-site clinical validations for this new system during 2020 Lyme disease season.
Qiagen (QGEN) Up 4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients
by Zacks Equity Research
QIAGEN's (QGEN) therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA.
QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access
by Zacks Equity Research
This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.
QIAGEN Partners Inovio to Develop Companion Diagnostics
by Zacks Equity Research
QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.
QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.
Qiagen (QGEN) Tops Q1 Earnings Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 3.85% and -0.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for QIAGEN (QGEN)
by Zacks Equity Research
QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
by Zacks Equity Research
QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.
LabCorp (LH)-QIAGEN Form Alliance in In-Vitro Diagnostics
by Zacks Equity Research
LabCorp's (LH) wide exposure in the companion diagnostics space further enhances QIAGEN's personalized health collaborations with the pharmaceutical bigwigs.
QIAGEN Unveils Liquid Biopsy Workflows & Panels, Widens Suite
by Zacks Equity Research
QIAGEN (QGEN) is progressing well with its testing menu expansion strategy.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
QIAGEN Partners With Tecan to Advance QFT-Plus Diagnostic Test
by Zacks Equity Research
QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.
Why Is Qiagen (QGEN) Up 8.1% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intuitive Surgical Gets FDA Nod for Ion Endoluminal System
by Zacks Equity Research
The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.